Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|August 24, 2020
Head and neck mucosal melanoma: The United Kingdom national guidelinesPablo Nenclares, Derfel Ap Dafydd, Izhar Bagwan, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 studySeverine Vermeire, Peter L Lakatos, Timothy Ritter, et al.
Head & Neck|August 28, 2021
What is the role of the surgeon in the management of head and neck mucosal melanoma in the immunotherapy era?Mark Edmond, Pablo Nenclares, Kevin Harrington, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 studySilvio Danese, Jean-Frederic Colombel, Milan Lukas, et al.
Nature Medicine|February 12, 2020
Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanomaBenjamin P Fairfax, Chelsea A Taylor, Robert A Watson, et al.
Drug and Alcohol Dependence|August 3, 2007
Modelling the hepatitis C virus epidemic in AustraliaKarina Razali, Hla Hla Thein, Jane Bell, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 2025
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 studyPaul Lorigan, Theresa Michelle Medina, Marta Nyakas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2020
Ano-uro-genital mucosal melanoma UK national guidelinesHenry G Smith, Izhar Bagwan, Ruth E Board, et al.
BMJ Open|March 3, 2026
Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocolBenjamin A Fisher, Anna Rowe, Chris Hodson, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2023
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM)Alimu Dayimu, Avinash Gupta, Rubeta N Matin, et al.
Pageof 4